Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The French National Authority for Health (HAS) released new set of decisions in relation to add-on reimbursement of medical devices in August

French National Authority for Health (HAS) released new decisions about add-on and medical aid reimbursement of medical devices from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in August 2017. They include different types of stents and stent-grafts for multiple indications (coronary, peripheral vascular), mechanical thrombectomy devices for stroke, medical devices applied for treatment of ulcer of venous origin, remote monitoring for Implantable Cardioverter Defibrillator Systems (ICDS):

  • Two decisions in relation to coronary stents and balloons:
    • PANTERA LUX, coronary paclitaxel-releasing balloon (application for registration, approved only for two of three proposed indications/ first restenosis after stenting procedure with bare metal stents or drug-eluting stents)
    • COROFLEX ISAR NEO, coronary drug-eluting stent (application for registration, approved)
  • Two decisions for peripheral vascular stent and drug-coated balloon:
    • GORE VIABAHN, peripheral vascular stent (request for amendment + renewal of registration, approved)
    • LUTONIX 035, peripheral vascular paclitaxel-releasing balloon (application for registration, approved)
  • Three decisions for medical devices applied for intracranial thrombectomy:
  • Two decisions for devices ulcer of venous origin:

Additionally, HAS approved 15 applications for renewal of registration of systems for remote monitoring for Implantable Cardioverter Defibrillator Systems (ICDS) that manufactured by five medtech companies:

Other decisions of CNEDiMTS in August include:

See list of decisions here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.